Consumer medicine information

Act-HIB

Haemophilus B conjugate vaccine

BRAND INFORMATION

Brand name

Act-HIB

Active ingredient

Haemophilus B conjugate vaccine

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Act-HIB.

What is in this leaflet

This leaflet answers common questions about Act-HIB.

It does not contain all the available information.

It does not take the place of talking to your doctor.

All medicines, including vaccines, have risks and benefits. Your doctor has weighed the risks of your child having Act-HIB against the benefits they expect it will have.

This vaccine has been prescribed for your child. Do not pass it on to others.

If you have any concerns about this vaccine, ask your doctor.

Keep this leaflet. You may need to read it again.

What Act-HIB is used for

Act-HIB is a vaccine that helps protect your child against Haemophilus Influenzae type b infections.

This vaccine does not provide protection against infections due to other types of Haemophilus Influenzae or against cases of meningitis of other origins.

The vaccine may be administered to children from 2 months of age to 5 years of age.

Under no circumstances can the tetanus protein contained in this vaccine be used to replace the usual tetanus vaccination.

When an injection of Act-HIB is given, the immune system (body’s natural defences) will protect against Haemophilus Influenzae type b infections. However, as with any vaccine, Act-HIB may not protect 100% of vaccinated individuals.

Before your child is given Act-HIB

When your child must not be given it

Do not have Act-HIB if your child has an allergy to:

  • the active substance or any of the other ingredients of Act-HIB listed at the end of this leaflet.
  • formaldehyde.

Symptoms of an allergic reaction may include:

  • shortness of breath, wheezing or difficulty breathing
  • swelling of the face, lips, tongue or other parts of the body
  • skin rash, itching or hives

Do not have Act-HIB if your child:

  • has had a life-threatening reaction after previous administration of this vaccine or a vaccine containing the same substances.
  • has an illness with febrile or acute infection. The vaccination should be postponed until after your child has recovered.

Before your child is given it

Tell your doctor before vaccination if your child has a poor immune response (immunosuppression) due to disease or medicines, because your response to the vaccine may be limited.

Tell your doctor if your child has a bleeding disorder.

Tell your doctor if your child has an allergy to latex.

Taking other medicines

Tell your doctor if your child is taking any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food shop.

Having other vaccines

Tell your doctor if your child has had any vaccines in the last 4 weeks.

Your doctor will advise you if Act-HIB is to be given with another vaccine as a separate injection.

How Act-HIB is given

Act-HIB is administered to your child by your doctor or nurse.

Act-Hib is given as an injection. For children under the age of 24 months, Act-HIB is injected into the upper thigh muscle. In older children who have started walking, the vaccine is usually injected into the upper arm muscle.

How much is given

Infants:

  • Before 6 months of age, administration of 3 successive 0.5mL doses at intervals of one to two months.
  • Between 6 and 12 months of age, administration of 2 successive 0.5mL doses at intervals of one to two months.
  • This is followed in both cases by a booster dose as per the National Immunisation Schedule.

Children:

  • In children over 12 months of age, a single dose of 0.5mL.

If you miss a dose

If your child misses a dose, talk to your doctor and arrange another visit as soon as possible.

After having Act-HIB

Things you must do

Keep an updated record of your vaccinations.

Keep follow-up appointments with your doctor or clinic. It is important for your child to have follow-up doses of Act-HIB at the appropriate times to make sure the vaccines are providing protection against Haemophilus Influenzae type b.

Report any side effects to your doctor.

Side effects

Tell your doctor or pharmacist as soon as possible if your child does not feel well after having Act-HIB.

Act-HIB may have unwanted side effects in a few people. All medicines, including vaccines, can cause side effects. Sometimes they are serious, most of the time they are not.Your child may need medical treatment if you get some of the side effects.

Do not be alarmed by this list of possible side effects. Your child may not experience any of them.

Ask your doctor or pharmacist to answer any questions you may have.

Tell your doctor or pharmacist if you notice any of the following and they worry you:

  • Fever
  • Irritability
  • Injection site reactions such as pain, redness (erythema), swelling, inflammation, hardening of the skin (induration)
  • Vomiting
  • Crying (uncontrollable or abnormal)
  • Unusual tiredness
  • Runny nose
  • Diarrhoea

These are the more common side effects of Act-HIB. Mostly these are mild and short-lived.

Tell your doctor immediately if you notice any of the following:

  • Extensive limb swelling of the vaccinated limb
  • Large injection site reactions (more than 50 mm) such as pain, redness, swelling and/or inflammation or hardening of the skin.
  • Swelling (oedema) of lower limbs with symptoms that may include blue or purple coloration of the skin (cyanosis), redness, transient discoloration of the skin (purpura).
  • Itchy rash (urticaria), rash generalised, rash, itching (pruritus), face swelling (oedema), laryngeal swelling (oedema)

If any of the following happen, tell your doctor immediately and go to Accident and Emergency at your nearest hospital:

  • Allergic (hypersensitivity) reactions, such as itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body.
  • Convulsions (with or without fever)

Other side effects not listed above may occur in some patients.

Tell your doctor or pharmacist if you notice anything that is making your child feel unwell.

Storing Act-HIB

Act-HIB is usually stored in the doctor’s surgery or clinic, or at the pharmacy. However, if you need to store Act-HIB:

  • Keep out of the reach and sight of children.
  • Keep Act-HIB in the original pack until it is time for it to be given.
  • Store in a refrigerator (2°C - 8°C). Do not freeze.
    Freezing destroys the vaccine.

Do not use Act-HIB after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

Product description

What it looks like

Act-HIB is a freeze-dried powder for reconstitution with diluent for injection. Following reconstitution, the solution is clear.

Each pack of Act-HIB contains a single dose vial (containing powder for reconstitution) and 0.5 mL of diluent in a syringe.

Ingredients

The active substance is Haemophilus type b polysaccharide 10mcg conjugated to tetanus protein (18 - 30 mcg per 0.5mL dose).

The other ingredients are: trometamol, sucrose, sodium chloride and water for injections.

Name and address of sponsor

Australia:

sanofi-aventis australia pty ltd
12-24 Talavera Road
Macquarie Park
NSW 2113, Australia
Telephone: 1800 818 806

New Zealand:

sanofi-aventis new zealand limited
Level 8, 56 Cawley Street
Ellerslie
Auckland
New Zealand
Telephone: 0800 283 684

Date of Preparation

18 March 2020

act-ccdsv9-cmiv2-18mar20

Published by MIMS May 2020

BRAND INFORMATION

Brand name

Act-HIB

Active ingredient

Haemophilus B conjugate vaccine

Schedule

S4

 

1 Name of Medicine

Act-HIB Haemophilus type b conjugate vaccine (conjugated to tetanus protein).
Haemophilus type b polysaccharide.

2 Qualitative and Quantitative Composition

Act-HIB contains the capsular polysaccharide of the Haemophilus influenzae type b bacterial strain conjugated to tetanus protein. The polysaccharide consists of polyribosyl ribitol phosphate (PRP).

Active ingredients.

Haemophilus type b polysaccharide (10 micrograms) conjugated to tetanus protein (18-30 micrograms).
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Act-HIB is a freeze-dried powder for reconstitution with diluent for injection. Following reconstitution, the solution is limpid and colourless.

4 Clinical Particulars

4.1 Therapeutic Indications

Act-HIB is indicated for use in infants from 2 months to 5 years of age for active immunization against invasive disease caused by the Haemophilus influenzae type b.
The vaccine does not protect against infections due to other types of Haemophilus influenzae nor against meningitis from other origins.

Note.

Under no circumstances should the tetanus protein component of this vaccine be substituted for the routine tetanus vaccination.

4.2 Dose and Method of Administration

After reconstitution, the vaccine should be administered via the intramuscular or subcutaneous route.
The preferred injection site for children under 2 years of age is anterolateral thigh. In older children the vaccine may be given at the anterolateral thigh or deltoid region.
Vaccine injections should not be given in the dorsogluteal site or upper outer quadrant of the buttock because of the possibility of a suboptimal immune response.
For further information, refer to the current Immunisation Handbook.

Infants.

2-6 months age.

3 injections at 1 or 2 month intervals.

7-11 months age.

2 injections at 1 or 2 months intervals.
This is followed in both cases by a booster at 18 months.

In children over 12 months.

A single injection.
The reconstituted product must be used immediately after reconstitution.
Once reconstituted, the vaccine must not be mixed with any other vaccine or medicinal product. Therefore, separate injection sites and different syringes should be used in case of concomitant administration.
Act-HIB is for single use only and must not be used in more than one individual. Discard any remaining unused contents.
Act-HIB can be incorporated into the recommended childhood immunization schedule, in accordance with the DTP schedule. However, the administration of Act-HIB should be carried out in a different site from those used for the other recommended vaccinations: diphtheria, tetanus, pertussis, poliomyelitis and measles, mumps and rubella.

4.3 Contraindications

Known systemic hypersensitivity to any component of Act-HIB in particular the tetanus protein or formaldehyde. Life-threatening reaction after previous administration of the vaccine or vaccine containing the same substances.
Vaccination must be postponed in case of febrile or acute disease.

4.4 Special Warnings and Precautions for Use

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following administration of the vaccine.
Do not administer by intravascular injection: ensure that the needle does not penetrate a blood vessel.
As with all injectable vaccines, the vaccine must be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.
Prior to administration of any dose of Act-HIB, the parent or guardian of the recipient must be asked about their personal history, family history, and recent health status, including immunisation history, current health status and any adverse event after previous immunisations. In subjects who have a history of serious or severe reaction within 48 hours of a previous injection with a vaccine containing similar components, the course of the vaccination must be carefully considered.
The anticipated antibody response may not be obtained in individuals with impaired immune function due to drugs or disease.
Experience with native populations (Alaska, Native American Indians) generally suggests that response to all conjugated Haemophilus influenzae type b vaccines in these populations may be significantly lower than in Caucasians. The possibility of a lower antibody response in the Australian aboriginal population should be borne in mind.
As with most vaccines, the expected antibody response may not be achieved in 100% of cases.
Information is currently lacking on the value of vaccinating with Act-HIB after exposure to infection.
Cases of Haemophilus influenzae type b disease may occur in the weeks after vaccination prior development of an adequate antibody response.
The potential risk of apnoea and the need for respiratory monitoring for 48-72 h should be considered when administering the primary immunisation series to very premature infants (born ≤ 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.
The tip caps of the prefilled syringes contain a natural rubber latex derivative, which may cause allergic reactions in latex sensitive individuals.
Syncope can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent falling and injury and to manage syncope.

Use in the elderly.

No data available.

Paediatric use.

See Section 4.4 Special Warnings and Precautions for Use.

Effects on laboratory test.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Concurrent administration of Act-HIB and DTP vaccines results in a somewhat lower antibody response to the diphtheria and pertussis components, although the levels are above those considered to be protective.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data available.
(Category B2)
Vaccination of adults against Hib is uncommon. Data on the use of this vaccine in pregnant women are limited. Therefore, administration of the vaccine during pregnancy is not recommended. Act-HIB should be given to pregnant women only if clearly needed and following an assessment of the risks and benefits.
Vaccination of adults against Hib is uncommon. It is not known whether Act-HIB is secreted in human milk. Caution must be exercised when Act-HIB is administered to a nursing mother.

4.7 Effects on Ability to Drive and Use Machines

No studies on the effects on the ability to drive and use machines have been performed.

4.8 Adverse Effects (Undesirable Effects)

Clinical trials experience.

In studies on healthy children aged 2 months or more, Act-HIB was generally well tolerated. The following adverse effects were observed during the 72 hours after vaccination:

Local.

Erythema, induration at the injection site, pain, swelling and/or inflammation.

Systemic.

Irritability, unusual tiredness, rhinorrhoea, crying, fever, diarrhoea and vomiting.

Rare events.

During studies with Haemophilus influenzae type b polysaccharide vaccines, convulsions, early onset Haemophilus b disease and Guillain Barre syndrome have occurred rarely. However, a causal relationship between these side effects and the vaccination was not established. As with any vaccine, there is the possibility that broad use of Act-HIB could reveal adverse reactions not observed in clinical trials.

Adverse reactions from post-marketing surveillance.

Based on spontaneous reporting, the following adverse events have also been reported after commercial use. As exact incidence rates cannot be calculated precisely, their frequency is qualified as "not known".

Immune system disorders.

Hypersensitivity reactions.

Nervous system disorders.

Convulsions (with or without fever).

Skin and subcutaneous tissue disorders.

Urticaria, rash generalised, rash, pruritus.
Face oedema, laryngeal oedema (suggestive of a possible hypersensitivity reaction).

General disorders and application site conditions.

Extensive limb swelling of the vaccinated limb (from the injection site beyond one or both joints).
Large injection site reactions (> 50 mm) such as pain, erythema, swelling and/or inflammation, or indurations.
Oedema of lower limbs: Oedematous reaction affecting one or both lower limbs may occur following vaccination with Haemophilus influenzae type b containing vaccines. If this reaction occurs, it does so mainly after primary injections and is observed within the first few hours following vaccination. Associated symptoms may include cyanosis, redness, transient purpura and severe crying.

Reporting of suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at http://www.tga.gov.au/reporting-problems.

4.9 Overdose

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Therapeutic class.

J07A (Bacterial vaccines)/ G (Haemophilus influenzae B vaccines)/ 01 (Haemophilus influenzae B, purified antigen conjugated).
When administered to humans Act-HIB results in an IgG specific anti-PRP response in infants. This response is T-lymphocyte dependent and is characterised by establishment of immunological memory. Antibody response appears to be greater following subcutaneous administration as compared to intramuscular administration.
Although information on the protective efficacy of the Act-HIB from field trials is limited, Act-HIB has been shown to induce antibody levels well above those known to be protective against invasive disease due to Haemophilus influenzae type b bacterial strains, in 97-100% vaccinees.
Antibodies generated by Act-HIB are directed against infection caused by the Haemophilus influenzae type b bacterial strain only, Act-HIB does not generate antibodies against other organisms, including other strains of Haemophilus influenzae.
Study of the functional activity of the anti-PRP antibodies induced by Act-HIB (Haemophilus b conjugate vaccine) in infants and children, showed opsonization and intracellular phagocytic killing properties.

5.2 Pharmacokinetic Properties

No pharmacokinetic studies have been performed.

5.3 Preclinical Safety Data

No data available.

Genotoxicity.

No data available.

Carcinogenicity.

No data available.

6 Pharmaceutical Particulars

6.1 List of Excipients

Trometamol, sucrose, sodium chloride, water for injection.
No antimicrobial preservative is added.

6.2 Incompatibilities

Do not mix Act-HIB in the same syringe as other vaccines or medicinal products.

6.3 Shelf Life

48 months.

6.4 Special Precautions for Storage

Store at 2°C to 8°C (Refrigerate. Do not freeze). Do not use after the expiry date.

6.5 Nature and Contents of Container

Single dose vial with powder for reconstitution and 0.5 mL diluent syringe with or without separate needles.
Pack of 1 or 10.
Not all pack sizes may be marketed.

6.6 Special Precautions for Disposal

After use, any remaining vaccine and container must be disposed of safely according to locally agreed procedures.

6.7 Physicochemical Properties

Not applicable.

7 Medicine Schedule (Poisons Standard)

S4 Prescription Only Medicine.

Summary Table of Changes